Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 366 articles:
HTML format
Text format



Single Articles


    May 2018
  1. SETHI TK, Reddy NM
    Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies.
    Leuk Lymphoma. 2018 May 9:1-13. doi: 10.1080/10428194.2018.1466296.
    PubMed     Text format     Abstract available


  2. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


  3. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Text format     Abstract available


    April 2018
  4. LUDMIR EB, Milgrom SA, Pinnix CC, Gunther JR, et al
    Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure().
    Leuk Lymphoma. 2018 Apr 26:1-8. doi: 10.1080/10428194.2018.1460825.
    PubMed     Text format     Abstract available


  5. NANNI L, Broccoli A, Nanni C, Argnani L, et al
    Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1443336.
    PubMed     Text format    


  6. BEYGI S, Sadashiv S, Reilly JB, Khan C, et al
    Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
    Leuk Lymphoma. 2018 Apr 4:1-15. doi: 10.1080/10428194.2018.1443332.
    PubMed     Text format     Abstract available


  7. ZAJA F, Salvi F, Rossi M, Sabattini E, et al
    Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1452208.
    PubMed     Text format     Abstract available


  8. PINNIX CC, Wirth A, Milgrom SA, Andraos TY, et al
    Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1452211.
    PubMed     Text format     Abstract available


    March 2018
  9. WIGHT JC, Hawkes EA, Berlangieri SU, Khor R, et al
    An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-3. doi: 10.1080/10428194.2018.1452217.
    PubMed     Text format    


  10. ZHANG PP, Ding DZ, Shi B, Zhang SQ, et al
    Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452207.
    PubMed     Text format     Abstract available


  11. DHOLARIA BR, Hammond WA, Roy V, Sher T, et al
    Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience.
    Leuk Lymphoma. 2018 Mar 23:1-4. doi: 10.1080/10428194.2018.1452220.
    PubMed     Text format    


  12. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Text format     Abstract available


    February 2018
  13. FEUGIER P, Brice P, Maynadie M, Franchi-Rezgui P, et al
    Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
    Leuk Lymphoma. 2018 Feb 28:1-4. doi: 10.1080/10428194.2018.1434878.
    PubMed     Text format    


  14. PEIL-GRUN A, Trenker C, Gorg K, Neesse A, et al
    Diagnostic accuracy and interobserver agreement of contrast-enhanced ultrasound in the evaluation of residual lesions after treatment for malignant lymphoma and testicular cancer: a retrospective pilot study in 52 patients().
    Leuk Lymphoma. 2018 Feb 27:1-6. doi: 10.1080/10428194.2018.1439170.
    PubMed     Text format     Abstract available


  15. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed     Text format    


  16. HAN W, Ibarra G, Gupta M, Yin Y, et al
    Elevated GLI3 expression in germinal center diffuse large B cell lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439169.
    PubMed     Text format    


  17. BURNELLI R, Rinieri S, Rondelli R, Todesco A, et al
    Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy.
    Leuk Lymphoma. 2018 Feb 16:1-10. doi: 10.1080/10428194.2018.1435872.
    PubMed     Text format     Abstract available


  18. STECCO A, Buemi F, Iannessi A, Carriero A, et al
    Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434881.
    PubMed     Text format     Abstract available


  19. MARRERO WD, Cruz-Chacon A, Cabanillas F
    Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?
    Leuk Lymphoma. 2018 Feb 7:1-3. doi: 10.1080/10428194.2018.1427863.
    PubMed     Text format    


    January 2018
  20. VILLA D, Sehn LH
    Double hit lymphoma: do we need a 'double hit' of intensive therapy?
    Leuk Lymphoma. 2018 Jan 25:1-2. doi: 10.1080/10428194.2018.1429606.
    PubMed     Text format    


  21. PHIPPS C, Lee YS, Ying H, Nagarajan C, et al
    The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Jan 18:1-6. doi: 10.1080/10428194.2017.1422863.
    PubMed     Text format     Abstract available


  22. KOJIMA M, Carreras J, Kikuti YY, Miyaoka M, et al
    A case of diffuse large B-cell lymphoma with MYC gene cluster amplification related to chromothripsis.
    Leuk Lymphoma. 2018 Jan 18:1-5. doi: 10.1080/10428194.2017.1421753.
    PubMed     Text format    


  23. DRACH J, Huang H, Samoilova O, Belch A, et al
    Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the random
    Leuk Lymphoma. 2018 Jan 17:1-8. doi: 10.1080/10428194.2017.1365855.
    PubMed     Text format     Abstract available


  24. COLLINS GP, Rueda A, Salles G, von Tresckow B, et al
    Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
    Leuk Lymphoma. 2018 Jan 16:1-8. doi: 10.1080/10428194.2017.1421762.
    PubMed     Text format     Abstract available


  25. SONBOL MB, Hilal T, Dueck AC, Rosenthal AC, et al
    A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
    Leuk Lymphoma. 2018 Jan 10:1-7. doi: 10.1080/10428194.2017.1416368.
    PubMed     Text format     Abstract available


  26. DITTUS C, Grover N, Ellsworth S, Tan X, et al
    Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Leuk Lymphoma. 2018 Jan 5:1-7. doi: 10.1080/10428194.2017.1416365.
    PubMed     Text format     Abstract available


  27. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Text format     Abstract available


  28. WEVER CM, Geoffrion D, Grande BM, Yu S, et al
    The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.
    Leuk Lymphoma. 2018 Jan 3:1-16. doi: 10.1080/10428194.2017.1413186.
    PubMed     Text format     Abstract available


    December 2017
  29. LAMAR ZS, Dothard A, Kennedy L, Isom S, et al
    Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
    Leuk Lymphoma. 2017 Dec 18:1-7. doi: 10.1080/10428194.2017.1410889.
    PubMed     Text format     Abstract available


  30. ALJOHANI N, Choi SJ, Day AG, Alhejaily A, et al
    Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival.
    Leuk Lymphoma. 2017 Dec 18:1-9. doi: 10.1080/10428194.2017.1410883.
    PubMed     Text format     Abstract available


  31. ARIMA H, Fujimoto M, Nishikori M, Kitano T, et al
    Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 18:1-11. doi: 10.1080/10428194.2017.1410884.
    PubMed     Text format     Abstract available


  32. FU J, Upshaw J, Cohen J, Rodday AM, et al
    Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review.
    Leuk Lymphoma. 2017 Dec 7:1-5. doi: 10.1080/10428194.2017.1406086.
    PubMed     Text format    


  33. SU C, Nguyen KA, Bai HX, Cao Y, et al
    Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1410886.
    PubMed     Text format     Abstract available


  34. BLOMBERY P, Lickiss J, Dickinson M
    The price of success-health economics of personalized diffuse large B-cell lymphoma treatment.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1408088.
    PubMed     Text format    


  35. CHEN AI, Leonard JT, Okada CY, Gay ND, et al
    Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1406085.
    PubMed     Text format     Abstract available


  36. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed     Text format    


    November 2017
  37. GIULINO-ROTH L, O'Donohue T, Chen Z, Trippett TM, et al
    Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
    Leuk Lymphoma. 2017 Nov 29:1-10. doi: 10.1080/10428194.2017.1403601.
    PubMed     Text format     Abstract available


  38. DREYLING M, Aurer I, Cortelazzo S, Hermine O, et al
    Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
    Leuk Lymphoma. 2017 Nov 27:1-15. doi: 10.1080/10428194.2017.1403602.
    PubMed     Text format     Abstract available


  39. SARID N, Sherban A, Bendet A, Adam S, et al
    CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines.
    Leuk Lymphoma. 2017 Nov 27:1-6. doi: 10.1080/10428194.2017.1403023.
    PubMed     Text format     Abstract available


  40. KEMPIN S, Finger PT, Gale RP, Rescigno J, et al
    A cluster of vitreoretinal lymphoma in New York with possible link to the Chernobyl nuclear disaster.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1403025.
    PubMed     Text format    


  41. KO SH, Lee JH, Lee JH, Park HS, et al
    Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
    Leuk Lymphoma. 2017 Nov 22:1-11. doi: 10.1080/10428194.2017.1399310.
    PubMed     Text format     Abstract available


  42. BODY S, Esteve-Arenys A, Recasens-Zorzo C, Troussard X, et al
    A mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor beta agonists toward tumor burden.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399313.
    PubMed     Text format    


  43. TAN CRC, Barta SK, Lee J, Rudek MA, et al
    Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.
    Leuk Lymphoma. 2017 Nov 21:1-10. doi: 10.1080/10428194.2017.1403597.
    PubMed     Text format     Abstract available


  44. GLEESON M, Peckitt C, Cunningham D, Gibb A, et al
    Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Leuk Lymphoma. 2017 Nov 9:1-10. doi: 10.1080/10428194.2017.1393671.
    PubMed     Text format     Abstract available


  45. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Text format     Abstract available


  46. NEUMANN DR, Marini BL, Phillips TJ, Wilcox RA, et al
    Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
    Leuk Lymphoma. 2017 Nov 6:1-10. doi: 10.1080/10428194.2017.1393672.
    PubMed     Text format     Abstract available


    October 2017
  47. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.
    PubMed     Text format    


  48. ITOH K, Igarashi T, Irisawa H, Aotsuka N, et al
    Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
    Leuk Lymphoma. 2017 Oct 30:1-8. doi: 10.1080/10428194.2017.1390233.
    PubMed     Text format     Abstract available


  49. BELTRAN BE, Quinones P, Sanchez G, Paredes A, et al
    Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
    Leuk Lymphoma. 2017 Oct 30:1-3. doi: 10.1080/10428194.2017.1393666.
    PubMed     Text format    


  50. CHEN Q, Staton AD, Ayer T, Goldstein DA, et al
    Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Oct 25:1-10. doi: 10.1080/10428194.2017.1390230.
    PubMed     Text format     Abstract available


  51. ZAGADAILOV EA, Corman S, Chirikov V, Johnson C, et al
    Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.
    PubMed     Text format     Abstract available


  52. JUSKEVICIUS D, Muller A, Hashwah H, Lundberg P, et al
    Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1387903.
    PubMed     Text format     Abstract available


  53. QUNAJ L, Castillo JJ, Olszewski AJ
    Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2017 Oct 11:1-9. doi: 10.1080/10428194.2017.1387912.
    PubMed     Text format     Abstract available


  54. VITAGLIANO O, Trastulli F, Cacace F, Leone S, et al
    Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Leuk Lymphoma. 2017 Oct 11:1-4. doi: 10.1080/10428194.2017.1387910.
    PubMed     Text format    


  55. CENCINI E, Puccini B, Rigacci L, Fabbri A, et al
    Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Leuk Lymphoma. 2017 Oct 10:1-7. doi: 10.1080/10428194.2017.1387909.
    PubMed     Text format     Abstract available


  56. SU C, Nguyen KA, Bai HX, Balaji D, et al
    Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.
    Leuk Lymphoma. 2017 Oct 5:1-7. doi: 10.1080/10428194.2017.1379078.
    PubMed     Text format     Abstract available


  57. JACHIET V, Mekinian A, Carrat F, Grignano E, et al
    Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.
    Leuk Lymphoma. 2017 Oct 3:1-7. doi: 10.1080/10428194.2017.1379075.
    PubMed     Text format     Abstract available


    September 2017
  58. XU ZZ, Shen JK, Zhao SQ, Li JM, et al
    Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 27:1-10. doi: 10.1080/10428194.2017.1379077.
    PubMed     Text format     Abstract available


  59. KAMRAN SC, Jacene HA, Chen YH, Mauch PM, et al
    Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
    Leuk Lymphoma. 2017 Sep 22:1-7. doi: 10.1080/10428194.2017.1376745.
    PubMed     Text format     Abstract available


  60. MAZIARZ RT, Hao Y, Guerin A, Gauthier G, et al
    Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 21:1-10. doi: 10.1080/10428194.2017.1375100.
    PubMed     Text format     Abstract available


  61. HERTING F, Friess T, Umana P, Middleton S, et al
    Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Sep 15:1-4. doi: 10.1080/10428194.2017.1376740.
    PubMed     Text format    


  62. BENTUR OS, Gurion R, Gafter-Gvili A, Gatt M, et al
    Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375102.
    PubMed     Text format     Abstract available


  63. DIMOU M, Roumelioti M, Dimitrakopoulou A, Bitsani C, et al
    High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.
    Leuk Lymphoma. 2017 Sep 13:1-4. doi: 10.1080/10428194.2017.1375108.
    PubMed     Text format    


  64. L'ABBATE A, Iacobucci I, Lonoce A, Turchiano A, et al
    RALE051: a novel established cell line of sporadic Burkitt lymphoma.
    Leuk Lymphoma. 2017 Sep 11:1-4. doi: 10.1080/10428194.2017.1372580.
    PubMed     Text format     Abstract available


  65. JIANG L, Si T, Yu M, Zeng X, et al
    The tumor suppressive role of inhibin betaA in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 7:1-11. doi: 10.1080/10428194.2017.1372574.
    PubMed     Text format     Abstract available


  66. ARBOE B, Halgren Olsen M, Duun-Henriksen AK, Gorlov JS, et al
    Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Sep 4:1-10. doi: 10.1080/10428194.2017.1369061.
    PubMed     Text format     Abstract available


  67. RAESS PW, Moore SR, Cascio MJ, Dunlap J, et al
    MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.
    Leuk Lymphoma. 2017 Sep 3:1-8. doi: 10.1080/10428194.2017.1370547.
    PubMed     Text format     Abstract available


  68. CHOWDHRY AK, Fung C, Chowdhry VK, Bergsma D, et al
    A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Sep 1:1-8. doi: 10.1080/10428194.2017.1369063.
    PubMed     Text format     Abstract available


    August 2017
  69. WINTER A, Rybicki L, Shah SN, Jagadeesh D, et al
    Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Aug 30:1-7. doi: 10.1080/10428194.2017.1369065.
    PubMed     Text format     Abstract available


  70. DUVIC M, Bates SE, Piekarz R, Eisch R, et al
    Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
    Leuk Lymphoma. 2017 Aug 30:1-8. doi: 10.1080/10428194.2017.1361022.
    PubMed     Text format     Abstract available


  71. MEIGNAN M, Cottereau AS
    Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again....
    Leuk Lymphoma. 2017 Aug 30:1-3. doi: 10.1080/10428194.2017.1368078.
    PubMed     Text format    


  72. HIEMCKE-JIWA LS, Leguit RJ, Radersma-van Loon JH, Westerweel PE, et al
    Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
    Leuk Lymphoma. 2017 Aug 29:1-4. doi: 10.1080/10428194.2017.1369074.
    PubMed     Text format    


  73. PAUL U, Richter J, Stuhlmann-Laiesz C, Kreuz M, et al
    Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.
    Leuk Lymphoma. 2017 Aug 25:1-9. doi: 10.1080/10428194.2017.1365851.
    PubMed     Text format     Abstract available


  74. EL-GALALY TC, Cheah CY
    Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission.
    Leuk Lymphoma. 2017 Aug 22:1-3. doi: 10.1080/10428194.2017.1365863.
    PubMed     Text format    


  75. GUIDOT DM, Switchenko JM, Nastoupil LJ, Koff JL, et al
    Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
    Leuk Lymphoma. 2017 Aug 10:1-8. doi: 10.1080/10428194.2017.1361032.
    PubMed     Text format     Abstract available


  76. PARIKH A, Gopalakrishnan S, Freise KJ, Verdugo ME, et al
    Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Aug 10:1-9. doi: 10.1080/10428194.2017.1361024.
    PubMed     Text format     Abstract available



  77. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed     Text format    


  78. RYLAND GL, Jones K, McBean M, Khot A, et al
    Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361029.
    PubMed     Text format    


  79. HU B, Younes A, Westin JR, Turturro F, et al
    Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1359741.
    PubMed     Text format     Abstract available


  80. BUR H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, et al
    Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.
    Leuk Lymphoma. 2017 Aug 8:1-11. doi: 10.1080/10428194.2017.1344840.
    PubMed     Text format     Abstract available


  81. KATSUSHIMA H, Fukuhara N, Konosu-Fukaya S, Himuro M, et al
    Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation?
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1357172.
    PubMed     Text format    


  82. ZHANG Y, Fan Y, Ying Z, Song Y, et al
    Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?
    Leuk Lymphoma. 2017 Aug 3:1-10. doi: 10.1080/10428194.2017.1357171.
    PubMed     Text format     Abstract available


  83. JURCZAK W, Ramanathan S, Giri P, Romano A, et al
    Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
    PubMed     Text format     Abstract available


    July 2017
  84. PAPIN A, Le Gouill S, Chiron D
    Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Leuk Lymphoma. 2017 Jul 31:1-9. doi: 10.1080/10428194.2017.1357177.
    PubMed     Text format     Abstract available


  85. SANTIAGO V, Lazaryan A, McClune B, McKenna RW, et al
    Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Leuk Lymphoma. 2017 Jul 21:1-9. doi: 10.1080/10428194.2017.1352094.
    PubMed     Text format     Abstract available


  86. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Text format     Abstract available


  87. SANCHEZ-GONZALEZ B, Torres E, Ferraro Rosset MP, Calafell M, et al
    Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349906.
    PubMed     Text format    


  88. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Text format     Abstract available


  89. HILL BT, Smith MR, Shelley M, Jagadeesh D, et al
    A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Jul 11:1-5. doi: 10.1080/10428194.2017.1347932.
    PubMed     Text format     Abstract available


  90. SOUZA BMB, De Vito FB, Calado ML, Silva MV, et al
    Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1341978.
    PubMed     Text format     Abstract available


    June 2017
  91. LAI C, Roschewski M, Melani C, Pittaluga S, et al
    MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Leuk Lymphoma. 2017 Jun 22:1-4. doi: 10.1080/10428194.2017.1339882.
    PubMed     Text format    


  92. KIM J, Song YS, Lee JS, Lee WW, et al
    Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Leuk Lymphoma. 2017 Jun 20:1-8. doi: 10.1080/10428194.2017.1339877.
    PubMed     Text format     Abstract available


  93. CHAO C, Silverberg MJ, Chen LH, Xu L, et al
    Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Jun 13:1-9. doi: 10.1080/10428194.2017.1334121.
    PubMed     Text format     Abstract available


  94. VONDERHEID EC, Hou JS
    CD4+CD26- lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma.
    Leuk Lymphoma. 2017 Jun 9:1-10. doi: 10.1080/10428194.2017.1334123.
    PubMed     Text format     Abstract available


  95. HORING E, Staiger AM, Lenze D, Horn H, et al
    Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin.
    Leuk Lymphoma. 2017 Jun 5:1-4. doi: 10.1080/10428194.2017.1330469.
    PubMed     Text format    


  96. ROBAK T, Huang H, Jin J, Zhu J, et al
    Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1321750.
    PubMed     Text format     Abstract available


  97. GAUTAM A, Zhu Y, Ma E, Lee SY, et al
    Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1324160.
    PubMed     Text format     Abstract available


  98. HODKOFF A, Bentley P, Xu X
    Loss of CD3 and TCRgammadelta expression in a relapsed hepatosplenic T-cell lymphoma.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1326033.
    PubMed     Text format    


  99. HAZAR V, Kesik V, Karasu GT, Ozturk G, et al
    Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.
    Leuk Lymphoma. 2017 Jun 2:1-12. doi: 10.1080/10428194.2017.1330472.
    PubMed     Text format     Abstract available


  100. P VASSILAKOPOULOS T, Levidou G, Milionis V, Hartmann S, et al
    Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-gamma expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1289520.
    PubMed     Text format     Abstract available


    May 2017
  101. REBOURSIERE E, Gac AC, Garnier A, Salaun V, et al
    Increased frequencies of circulating and tumor-resident Vdelta1+ T cells in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 31:1-9. doi: 10.1080/10428194.2017.1321751.
    PubMed     Text format     Abstract available


  102. HESS G, Rule S, Jurczak W, Jerkeman M, et al
    Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326034.
    PubMed     Text format     Abstract available


  103. FAN Y, Zhang Y, Yang Z, Ying Z, et al
    Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 23:1-9. doi: 10.1080/10428194.2016.1277384.
    PubMed     Text format     Abstract available


  104. NAGAI H, Shimomura T, Takeuchi M, Hanada S, et al
    Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
    Leuk Lymphoma. 2017 May 16:1-7. doi: 10.1080/10428194.2017.1319054.
    PubMed     Text format     Abstract available


  105. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.
    PubMed     Text format    


  106. WAGNER-JOHNSTON ND, Lensing S, Noy A, Ratner L, et al
    High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1317095.
    PubMed     Text format     Abstract available


  107. DYSHLOVOY SA, Rast S, Hauschild J, Otte K, et al
    Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.
    Leuk Lymphoma. 2017 May 16:1-11. doi: 10.1080/10428194.2017.1317091.
    PubMed     Text format     Abstract available


  108. SUN HL, Atenafu EG, Tsang R, Kukreti V, et al
    Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 15:1-8. doi: 10.1080/10428194.2017.1307980.
    PubMed     Text format     Abstract available


  109. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Text format     Abstract available


  110. GUSS ZD, Madkhali A, Chen Q, Zhang Y, et al
    Intensity-modulated involved-site radiation therapy for non-Hodgkin lymphoma of the head and neck.
    Leuk Lymphoma. 2017 May 9:1-3. doi: 10.1080/10428194.2017.1312388.
    PubMed     Text format    


  111. HO JC, Dabaja BS, Milgrom SA, Smith GL, et al
    Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312381.
    PubMed     Text format     Abstract available


  112. FALAY O, Ozturk E, Bolukbasi Y, Gumus T, et al
    Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.
    Leuk Lymphoma. 2017;58:1114-1122.
    PubMed     Text format     Abstract available


    April 2017
  113. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  114. GUPTA NK, Wang CC, Mannis GN, Yu JJ, et al
    Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
    Leuk Lymphoma. 2017 Apr 10:1-4. doi: 10.1080/10428194.2017.1312374.
    PubMed     Text format    


  115. VALDEZ BC, Li Y, Murray D, Liu Y, et al
    The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Leuk Lymphoma. 2017 Apr 10:1-12. doi: 10.1080/10428194.2017.1306647.
    PubMed     Text format     Abstract available


  116. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  117. BARRACLOUGH AA, Cheah CY
    Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?
    Leuk Lymphoma. 2017 Apr 3:1-3. doi: 10.1080/10428194.2017.1307364.
    PubMed     Text format    


  118. HERLING M, Rengstl B, Scholtysik R, Hartmann S, et al
    Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology().
    Leuk Lymphoma. 2017;58:788-796.
    PubMed     Text format     Abstract available


    March 2017
  119. WU SC, Chapman JR, Vega F, Abrahams N, et al
    Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis.
    Leuk Lymphoma. 2017 Mar 28:1-4. doi: 10.1080/10428194.2017.1307358.
    PubMed     Text format    


  120. EL CHEIKH J, Massoud R, Haffar B, Fares E, et al
    Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307362.
    PubMed     Text format    


  121. KOSTOS L, Chai KL, Tam CS, Bazargan A, et al
    The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 23:1-4. doi: 10.1080/10428194.2017.1281414.
    PubMed     Text format    


  122. YOON KA, Kim MK, Eom HS, Lee H, et al
    Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 22:1-6. doi: 10.1080/10428194.2017.1300893.
    PubMed     Text format     Abstract available


  123. BORCHMANN S, von Tresckow B
    Novel agents in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Mar 20:1-12. doi: 10.1080/10428194.2017.1300898.
    PubMed     Text format     Abstract available


  124. CEDERLEUF H, Hjort Jakobsen L, Ellin F, de Nully Brown P, et al
    Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.
    Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1300888.
    PubMed     Text format     Abstract available


  125. CHEN Y, Zheng X, Chen B, Yang X, et al
    The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Mar 17:1-7. doi: 10.1080/10428194.2017.1300894.
    PubMed     Text format     Abstract available


  126. PHAM AQ, Broski SM, Habermann TM, Jevremovic D, et al
    Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue.
    Leuk Lymphoma. 2017 Mar 14:1-7. doi: 10.1080/10428194.2017.1300891.
    PubMed     Text format     Abstract available


  127. ALBANO D, Bosio G, Giubbini R, Bertagna F, et al
    18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.
    Leuk Lymphoma. 2017 Mar 7:1-7. doi: 10.1080/10428194.2017.1298754.
    PubMed     Text format     Abstract available


  128. SHUSTOV A, Coiffier B, Horwitz S, Sokol L, et al
    Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
    Leuk Lymphoma. 2017 Mar 7:1-7. doi: 10.1080/10428194.2017.1295143.
    PubMed     Text format     Abstract available


  129. NANNI C, Cottereau AS, Lopci E, Bodet-Milin C, et al
    Report of the 6th International Workshop on PET in lymphoma.
    Leuk Lymphoma. 2017 Mar 7:1-6. doi: 10.1080/10428194.2017.1298752.
    PubMed     Text format     Abstract available


  130. AKYUZ N, Albert-Konetzny N, Pott C, Callet-Bauchu E, et al
    MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma.
    Leuk Lymphoma. 2017 Mar 2:1-5. doi: 10.1080/10428194.2017.1296144.
    PubMed     Text format    


  131. YASUHIRO T, Sawada W, Klein C, Kozaki R, et al
    Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 i
    Leuk Lymphoma. 2017;58:699-707.
    PubMed     Text format     Abstract available


  132. LADIKOU EE, Kassi E
    The emerging role of estrogen in B cell malignancies.
    Leuk Lymphoma. 2017;58:528-539.
    PubMed     Text format     Abstract available


    February 2017
  133. LI XY, Geng LY, Zhou XX, Wei N, et al
    Kruppel-like factor 4 contributes to the pathogenesis of mantle cell lymphoma.
    Leuk Lymphoma. 2017 Feb 28:1-10. doi: 10.1080/10428194.2017.1292354.
    PubMed     Text format     Abstract available


  134. AKASAKA T, Lee YF, Novak AJ, Honjo G, et al
    Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene.
    Leuk Lymphoma. 2017 Feb 28:1-4. doi: 10.1080/10428194.2017.1289525.
    PubMed     Text format    


  135. COHEN JB, Maddocks KJ, Huang Y, Christian BA, et al
    A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Feb 20:1-2. doi: 10.1080/10428194.2017.1289527.
    PubMed     Text format    


  136. WANG L, Luo L, Gao Z, Liu SF, et al
    The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.
    Leuk Lymphoma. 2017 Feb 20:1-8. doi: 10.1080/10428194.2017.1289523.
    PubMed     Text format     Abstract available


  137. DING X, Chi J, Yang X, Hao J, et al
    Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells.
    Leuk Lymphoma. 2017 Feb 20:1-13. doi: 10.1080/10428194.2017.1289521.
    PubMed     Text format     Abstract available


  138. SCHMIDT-HANSEN M, Berendse S, Marafioti T, McNamara C, et al
    Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.
    Leuk Lymphoma. 2017 Feb 9:1-16. doi: 10.1080/10428194.2017.1287364.
    PubMed     Text format     Abstract available


  139. RAJYAGURU DJ, Bhaskar C, Borgert AJ, Smith A, et al
    Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database.
    Leuk Lymphoma. 2017 Feb 9:1-9. doi: 10.1080/10428194.2017.1287363.
    PubMed     Text format     Abstract available


  140. NIJLAND M, Jansen A, Doorduijn JK, Enting RH, et al
    Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma.
    Leuk Lymphoma. 2017 Feb 6:1-6. doi: 10.1080/10428194.2017.1285026.
    PubMed     Text format     Abstract available


    January 2017
  141. KAHL BS, Dreyling M, Gordon LI, Quintanilla-Martinez L, et al
    Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
    Leuk Lymphoma. 2017 Jan 31:1-12. doi: 10.1080/10428194.2017.1283036.
    PubMed     Text format     Abstract available


  142. AMIOT A, Jooste V, Gagniere C, Levy M, et al
    Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2017.1283033.
    PubMed     Text format     Abstract available


  143. HOLKOVA B, Yazbeck V, Kmieciak M, Bose P, et al
    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2017 Jan 19:1-9. doi: 10.1080/10428194.2016.1276287.
    PubMed     Text format     Abstract available


  144. CUBILLOS-ZAPATA C, Cordoba R, Avendano-Ortiz J, Lopez-Collazo E, et al
    Thalidomide analog CC-122 induces a refractory state in monocytes from patients with diffuse large B cell lymphoma.
    Leuk Lymphoma. 2017 Jan 16:1-6. doi: 10.1080/10428194.2016.1272686.
    PubMed     Text format    


  145. DHANAPAL V, Gunasekara M, Lianwea C, Marcus R, et al
    Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
    Leuk Lymphoma. 2017 Jan 16:1-9. doi: 10.1080/10428194.2016.1276288.
    PubMed     Text format     Abstract available


  146. SKARBNIK AP, Ma E, Lafeuille MH, Fortier J, et al
    Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.
    Leuk Lymphoma. 2017 Jan 16:1-8. doi: 10.1080/10428194.2016.1272688.
    PubMed     Text format    


  147. RAVI KUMAR AS, Tam C, Hofman MS
    FDG PET in follicular lymphoma: more than a staging test?
    Leuk Lymphoma. 2017 Jan 16:1-6. doi: 10.1080/10428194.2016.1272691.
    PubMed     Text format    


  148. BIRSEN R, Boutboul D, Crestani B, Seguin-Givelet A, et al
    Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma.
    Leuk Lymphoma. 2017 Jan 13:1-9. doi: 10.1080/10428194.2016.1271947.
    PubMed     Text format    


  149. WANG T, Xu P, Wang F, Zhou D, et al
    Effects of digoxin on cell cycle, apoptosis and NF-kappaB pathway in Burkitt's lymphoma cells and animal model.
    Leuk Lymphoma. 2017 Jan 13:1-16. doi: 10.1080/10428194.2016.1256480.
    PubMed     Text format     Abstract available


  150. BHATT S, Sarosiek KA, Lossos IS
    Interleukin 21 - its potential role in the therapy of B-cell lymphomas.
    Leuk Lymphoma. 2017;58:17-29.
    PubMed     Text format     Abstract available


    December 2016
  151. MORRISON VA, Weller EA, Habermann TM, Li S, et al
    Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  152. SEELIG DM, Ito D, Forster CL, Yoon UA, et al
    Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  153. GLEESON M, Hawkes EA, Peckitt C, Wotherspoon A, et al
    Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  154. STAIGER AM, Duppel J, Dengler MA, van der Kuip H, et al
    An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  155. BHETHANABHOTLA S, Jain S, Kapoor G, Mahajan A, et al
    Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  156. SHANMUGAM V, Dorfman DM
    An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    November 2016
  157. VOGT N, Dai B, Erdmann T, Berdel WE, et al
    The molecular pathogenesis of mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  158. HJALGRIM H, Rostgaard K
    Socio-economic risk patterns in Hodgkin lymphoma: not more, but new studies are warranted.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  159. OLSZEWSKI AJ
    Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  160. WASTERLID T, Nordstrom L, Freiburghaus C, Pedersen M, et al
    Frequency and clinical implications of SOX11 expression in Burkitt lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  161. BARTLETT NL, Smith MR, Siddiqi T, Advani RH, et al
    Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  162. LI T, Liu ZG, Liang PQ, Wang HT, et al
    Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  163. HUSSAINI MO, Rehman A, Chavez JC, Pinilla-Ibarz J, et al
    EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  164. BOND DA, Huang Y, Ruppert AS, Walker AR, et al
    Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  165. RAI A, Nastoupil LJ, Williams JN, Lipscomb J, et al
    Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  166. SHAO D, Gao Q, Liang CH, Wang SX, et al
    Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  167. CHOE H, Martin P
    Frontline autologous stem cell transplant for high-risk follicular lymphoma: forever elusive?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  168. FINNES HD, Chaffee KG, Call TG, Ding W, et al
    Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  169. MOSKOWITZ AJ, Horwitz SM
    Targeting histone deacetylases in T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  170. MOCCIA AA, Zucca E, Ghielmini M
    Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  171. WIRTH A, Dabaja B
    Optimizing treatment for nasal NK T-cell lymphoma.
    Leuk Lymphoma. 2016;57:2487-8.
    PubMed     Text format    


    October 2016
  172. VILLASBOAS JC, Ansell S
    Glancing at the complex biology of T-cells through the microenvironment of Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  173. PHILLIPS AA
    Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  174. ABRAMSON JS
    Bone marrow biopsies for staging of diffuse large B-cell lymphoma: are we looking too closely?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  175. GOLDSCHMIDT N, Darawshy F, Kleinstern G, Slyusarevsky E, et al
    The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  176. SEFTEL MD, Kuruvilla J, Kouroukis T, Banerji V, et al
    The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  177. LOHNEIS P, Wienert S, Klauschen F, Anagnostopoulos I, et al
    Fibrosis in low-grade follicular lymphoma - a link to the TH2 immune reaction.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  178. BENADIBA J, Rosilio C, Nebout M, Heimeroth V, et al
    Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  179. SVENDSEN P, Shekhrajka N, Nielsen KL, Vestergaard P, et al
    R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  180. ALONSO-ALVAREZ S, Vidriales MB, Caballero MD, Blanco O, et al
    The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  181. PELED JU, Jenq RR
    Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  182. TAJIMA K, Takahashi N, Ishizawa K, Murai K, et al
    Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  183. FORD RR, Ford RW, O'Neal M, Kahl BS, et al
    Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  184. CARR R, Ozdag H, Tekin N, Morris T, et al
    The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  185. MOON SH, Lee AY, Kim WS, Kim SJ, et al
    Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  186. ALKHATIB Y, Abdel Rahman Z, Kuriakose P
    Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    September 2016
  187. GASCOYNE DM, Banham AH
    The significance of FOXP1 in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  188. XIAO DY, Luo S, O'Brian K, Liu W, et al
    Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  189. PROCHAZKA V, Papajik T, Janikova A, Belada D, et al
    Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  190. DANESE MD, Griffiths RI, Gleeson ML, Dalvi T, et al
    Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  191. LI DH, Zhang XY, Du C, Zhang WH, et al
    Successful treatment of extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis with MEDA chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  192. MAURYA AK, Vinayak M
    PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  193. TANRIVERDI E, Acat M, Ozgul G, Abbasli K, et al
    Primary pulmonary lymphoma: four different and unusual radiologic and clinical manifestations.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  194. TOKUNAGA M, Uto H, Takeuchi S, Nakano N, et al
    Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  195. DE LA FUENTE MI, Haggiagi A, Moul A, Young RJ, et al
    Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  196. PAPAGEORGIOU SG, Kontos CK, Foukas PG, Panopoulou E, et al
    BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era.
    Leuk Lymphoma. 2016;57:2199-203.
    PubMed     Text format    


    August 2016
  197. LEVINE H, Leiba M, Bar Zeev Y, Keinan-Boker L, et al
    Risk of Hodgkin lymphoma according to immigration status and origin: a migrant cohort study of 2.3 million Jewish Israelis.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  198. SORIGUE M, Sancho JM, Morgades M, Moreno M, et al
    Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  199. CHAN KL, van der Weyden C, Khoo C, Lade S, et al
    Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  200. LOREE JM, Cai E, Sheffield BS, Dutz JP, et al
    Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  201. SONG Z, Wang H, Zhang H, Zhao K, et al
    Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  202. WONG-SEFIDAN I, Byrtek M, Zhou X, Friedberg JW, et al
    [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  203. MAGNANO L, Martinez A, Carreras J, Martinez-Trillos A, et al
    T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  204. GURTH M, Bernard V, Bernd HW, Schemme J, et al
    Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  205. KANEMASA Y, Shimoyama T, Sasaki Y, Tamura M, et al
    The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  206. OLSZEWSKI AJ
    Formulating a novel prognostic index for diffuse large B-cell lymphoma: T cells break the SILence.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  207. KAMPERS J, Orjuela-Grimm M, Schober T, Schulz TF, et al
    Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  208. KOLDEHOFF M, Ross SR, Duhrsen U, Beelen DW, et al
    Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  209. ASLAN A, Aras T, Ozdemir E
    Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  210. LE GUENNEC L, Maisonobe T, Choquet S, Massein A, et al
    Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  211. PARIKH RR, Yahalom J
    Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    July 2016
  212. GALANINA N, Jasielec J, Peace D, Smith SM, et al
    Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  213. YAMANAKA R, Morii K, Shinbo Y, Sano M, et al
    Late relapse of primary central nervous system lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  214. BARZENJE DA, Holte H, Fossa A, Ghanima W, et al
    Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  215. DANILOV AV, Li H, Press OW, Shapira I, et al
    Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  216. BURBURY KL, Alexander M, Westerman DA
    Risk of thromboembolism with lymphoma: myth or reality?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    June 2016
  217. HASNI MS, Berglund M, Yakimchuk K, Guan J, et al
    Estrogen receptor beta1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  218. BRAMMER JE, Khouri I, Marin D, Ledesma C, et al
    Stem cell transplantation outcomes in lymphoblastic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  219. ECONOMIDES MP, Mahale P, Turturro F, Hosry J, et al
    Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  220. MOCCIA AA, Hitz F, Hoskins P, Klasa R, et al
    Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  221. TRAVERSE-GLEHEN A, Verney A, Gazzo S, Jallades L, et al
    Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  222. KOSTAKOGLU L, Goy A, Martinelli G, Caballero D, et al
    FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  223. SON CH, Chiu BC, Koshy M
    Patterns of care and survival outcomes examining radiation therapy for advanced Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  224. BOLAND PJ, Hegerova LT, Williams SJ, McKenna RW, et al
    Successful treatment of two cases of classical Hodgkin lymphoma-associated hemophagocytic lymphohistiocyosis with R-CEPP.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  225. MOHANTY S, Mohanty A, Sandoval N, Tran T, et al
    Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  226. TOMITA N, Suzuki T, Miyashita K, Yamamoto W, et al
    The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  227. SEO JY, Hong J, Chun K, Jeong J, et al
    Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  228. HAMADAH AM, Thanarajasingam G, Gharaibeh KA, Finnes HD, et al
    Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  229. LUO H, Schmidt JA, Lee YS, Oltz EM, et al
    Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  230. UMINO K, Fujiwara SI, Ito S, Mashima K, et al
    Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  231. MARTIN P, Martinez-Velasquez J, Coronado MJ, Krsnik I, et al
    Association of DDX58 177 C > T polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  232. BORG IH, Bendtsen MD, Bogsted M, Madsen J, et al
    Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  233. BAETZ T, Chen BE, Couban S, Tom Kouroukis C, et al
    Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  234. ALDERUCCIO JP, Amarapurkar P, Chapman JR, Vega F, et al
    Characteristics and outcomes of lymphoblastic lymphoma - the University of Miami experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  235. ZINZANI PL, Rigacci L, Cox MC, Devizzi L, et al
    The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    May 2016
  236. BROCKELMANN PJ, Borchmann P, Engert A
    Current and future immunotherapeutic approaches in Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  237. ISIDORI A, Christofides A, Visani G
    Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  238. ITONAGA H, Taguchi J, Taguchi M, Taniguchi H, et al
    Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    



  239. Hadife, N., Nemos, C., Frippiat, J.-P., et al. Interleukin-24 mediates apoptosis in human B-cells through early activation of cell cycle arrest followed by late induction of the mitochondrial apoptosis pathway. Leuk. Lymphoma. 2013;54(3):587-597. http
    Leuk Lymphoma. 2016.
    PubMed     Text format    



  240. Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  241. KATSUSHIMA H, Fukuhara N, Ichikawa S, Ota Y, et al
    Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  242. VON TRESCKOW B, Morschhauser F, Szer J, Eichenauer DA, et al
    Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  243. DUNCAN VE, Ping Z, Varambally S, Peker D, et al
    Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  244. QI S, Yahalom J, Hsu M, Chelius M, et al
    Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  245. KAMSTRUP MR, Biskup E, Manfe V, Savorani C, et al
    Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  246. SPIEGEL JY, Cheung MC, Guirguis HR, Buckstein R, et al
    Validation of the NCCN-IPI in both de novo and transformed diffuse large B cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  247. NOVELLI S, Garcia-Muret P, Mozos A, Sierra J, et al
    Total body-surface area as a new prognostic variable in mycosis fungoides and Sezary syndrome.
    Leuk Lymphoma. 2016;57:1060-6.
    PubMed     Text format     Abstract available


  248. GOEBELER ME, Bargou R
    Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Leuk Lymphoma. 2016;57:1021-32.
    PubMed     Text format     Abstract available


  249. DREXLER HG, Eberth S, Nagel S, MacLeod RA, et al
    Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
    Leuk Lymphoma. 2016;57:1015-20.
    PubMed     Text format     Abstract available


  250. FERNANDEZ SG, Miranda JJ
    Bendamustine reactivates latent Epstein-Barr virus.
    Leuk Lymphoma. 2016;57:1208-10.
    PubMed     Text format    


  251. OZTURK E, Ozbalak M, Berk S, Erdogan I, et al
    Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
    Leuk Lymphoma. 2016;57:1211-4.
    PubMed     Text format    


    April 2016
  252. JOHRENS K, Trappe RU, Lenze D, Pfreundschuh M, et al
    Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  253. HUDNALL SD, Meng H, Lozovatsky L, Li P, et al
    Recurrent genetic defects in classical Hodgkin lymphoma cell lines.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  254. PILORGE S, Harel S, Ribrag V, Larousserie F, et al
    Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  255. LOGHAVI S, Wang SA, Jeffrey Medeiros L, Jorgensen JL, et al
    Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  256. DANISH HH, Liu S, Jhaveri J, Flowers CR, et al
    Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sezary syndrome.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  257. LEE HJ, Dai C, Wang M, Mouhayar E, et al
    Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  258. MOCIKOVA H, Pytlik R, Sykorova A, Janikova A, et al
    Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  259. MAR N, Digiuseppe JA, Dailey ME
    Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  260. KALPADAKIS C, Pangalis GA, Sachanas S, Rontogianni D, et al
    No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  261. YU JS, Hansen RN, Valderrama A, Carlson JJ, et al
    Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  262. MILGROM SA, Cheah CY, Pinnix CC, Smith GL, et al
    Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  263. HASSAN HM, Varney ML, Chaturvedi NK, Joshi SS, et al
    Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  264. GRATZINGER D, Jaffe ES
    Mucocutaneous ulcer: a mimic of EBV + diffuse large B cell lymphoma in the immunodeficiency setting.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  265. TAKAHASHI H, Miura K, Nakagawa M, Sugitani M, et al
    Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  266. ERDMANN T, Lenz G
    Approaching resistance to ibrutinib in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  267. SUAREZ JP, Dominguez ML, Gomez MA, Fernandez N, et al
    A unique case of in situ follicular lymphoma associated with two nonlymphoid malignancies.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    March 2016
  268. HAERY L, Mussakhan S, Waxman DJ, Gilmore TD, et al
    Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  269. TOWNSEND W, Johnson RJ, Pottinger BT, Counsell N, et al
    A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  270. PESSACH I, Petevi K, Gkirkas K, Stamouli M, et al
    Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  271. LEHNERS N, Kramer I, Schwarzbich MA, Ho AD, et al
    Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  272. IIOKA F, Honjo G, Misaki T, Toda Y, et al
    A unique subtype of diffuse large B-cell lymphoma primarily involving the bone marrow, spleen, and liver, defined by fluorodeoxyglucose-positron emission tomography combined with computed tomography.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  273. OROFINO N, Guidotti F, Cattaneo D, Sciume M, et al
    Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  274. SCHWARZBICH MA, Schoning T, Cremer M, Lisenko K, et al
    Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  275. TEO EC, Valdez BC, Ji J, Li Y, et al
    Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  276. CASTILLO JJ, Ghobrial IM, Treon SP
    Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  277. CHAN H, Jackson S, McLay J, Knox A, et al
    Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  278. CIAMMELLA P, Filippi AR, Simontacchi G, Buglione M, et al
    Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    February 2016
  279. GALANINA N, Petrich A, Nabhan C
    The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  280. STENSON M, Pedersen A, Hasselblom S, Nilsson-Ehle H, et al
    Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  281. KANEMASA Y, Shimoyama T, Sasaki Y, Sawada T, et al
    A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  282. WEI W, Sun W, Yu S, Yang Y, et al
    Butyrate production from high-fiber diet protects against lymphoma tumor.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  283. CAMUS V, Sarafan-Vasseur N, Bohers E, Dubois S, et al
    Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  284. BALZAROTTI M, Brusamolino E, Angelucci E, Carella AM, et al
    B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  285. GAC AC, Azar N, Daguindau E, Cartron G, et al
    Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  286. PAPADOPOULOS KP, Lopez-Jimenez J, Smith SE, Steinberg J, et al
    A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  287. GRIFFIN M, Fielding J, Ahmed N, Gandhi S, et al
    Remission of human immunodeficiency virus-related lymphoma in association with immune reconstitution on anti-retroviral therapy, without chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  288. ANSELL S
    How to select the frontline treatment for a patient with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    January 2016

  289. Chevalier T, mueller M, mougiakakos D, et al. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment. Leuk lymphoma. 2016. [epub ahead of print]. DOI: 10.3109/10428194.2015.1135432.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  290. MADDOCKS K, Hertlein E, Chen TL, Wagner AJ, et al
    A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  291. WHITE EC, Advani R, Hoppe RT
    2 Gy x 2 for palliative treatment of mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  292. VALTOLA J, Varmavuo V, Ropponen A, Selander T, et al
    Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  293. CHEAH CY, Mistry HE, Konoplev S, Fowler NH, et al
    Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  294. WOHLFARTH P, Carlstrom A, Staudinger T, Clauss S, et al
    Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  295. CASSIDY RJ, Jegadeesh N, Switchenko J, Danish H, et al
    The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  296. CHEUNG MC, Prica A, Graczyk J, Buckstein R, et al
    Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  297. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  298. OH EJ, Kim EK, Yang WI, Yoon SO, et al
    Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  299. KUCI V, Nordstrom L, Conrotto P, Ek S, et al
    SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  300. CHEVALIER N, Mueller M, Mougiakakos D, Ihorst G, et al
    Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  301. SAILLARD C, El Cheikh J, Granata A, Coso D, et al
    Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  302. AMORIM S, Fleury I, Mounier N, Harel S, et al
    Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  303. YUAN S, Yu J, Haverkos B, Su H, et al
    Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  304. NAM SJ, Kim S, Paik JH, Kim TM, et al
    An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  305. JAKOVIC LR, Mihaljevic BS, Andjelic BM, Bogdanovic AD, et al
    Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  306. ZAIMOKU Y, Takahashi W, Iwaki N, Saito C, et al
    Human herpesvirus-8-unrelated primary effusion lymphoma of the elderly not associated with an increased serum lactate dehydrogenase level: A benign sub-group of effusion lymphoma without chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  307. LIU WP, Wang XP, Zheng W, Ping LY, et al
    Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  308. DONG LH, Zhang LJ, Wang WJ, Lei W, et al
    Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  309. SORIGUE M, Junca J, Marce S, Cabezon M, et al
    The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies.
    Leuk Lymphoma. 2016;57:244-6.
    PubMed     Text format    


  310. PAPOUDOU-BAI A, Goussia A, Batistatou A, Stefanou D, et al
    The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas.
    Leuk Lymphoma. 2016;57:143-50.
    PubMed     Text format     Abstract available


  311. TOYA T, Nannya Y, Hangaishi A, Shiseki M, et al
    Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
    Leuk Lymphoma. 2016;57:961-4.
    PubMed     Text format    


  312. LEPRETRE S, Dartigeas C, Feugier P, Marty M, et al
    Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.
    Leuk Lymphoma. 2016;57:852-65.
    PubMed     Text format     Abstract available


  313. HOLKOVA B, Kmieciak M, Bose P, Yazbeck VY, et al
    Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
    Leuk Lymphoma. 2016;57:635-43.
    PubMed     Text format     Abstract available


  314. JAMANI K, Duggan P, Neri P, Bahlis N, et al
    Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.
    Leuk Lymphoma. 2016;57:557-62.
    PubMed     Text format     Abstract available


  315. LIPOWSKA-BHALLA G, Fagnano E, Illidge TM, Cheadle EJ, et al
    Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
    Leuk Lymphoma. 2016;57:1269-80.
    PubMed     Text format     Abstract available


  316. MAHALE P, Turturro F, Romaguera JE, Fowler N, et al
    The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia.
    Leuk Lymphoma. 2016;57:1487-90.
    PubMed     Text format    


  317. MIURA K, Takahashi H, Nakagawa M, Izu A, et al
    Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
    Leuk Lymphoma. 2016;57:1335-41.
    PubMed     Text format     Abstract available


    December 2015
  318. SUNDARARAJAN S, Chen H, Kumar A, Tus K, et al
    Donor-derived marginal zone lymphoma following reduced-intensity allogeneic peripheral blood stem cell transplant.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  319. ISONO N, Imai Y, Watanabe A, Moriya K, et al
    Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  320. KIM JH, Kim WS, Ryu K, Kim SJ, et al
    CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  321. ZENT CS, Bowen DA, Conte MJ, LaPlant BR, et al
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  322. VAN DEN BRAND M, van der Velden WJ, Diets IJ, Ector GI, et al
    Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  323. TSURUSAWA M, Watanabe T, Gosho M, Mori T, et al
    Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  324. SASSE S, Alram M, Muller H, Smardova L, et al
    Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  325. SOHANI AR, Abramson JS
    MYC/BCL2 double-expression vs. cell-of-origin classification in diffuse large B-cell lymphoma: do we need to know both?
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  326. NATARAJ V, Mathur N, Rani L, Gupta R, et al
    Serial assessment of circulating T regulatory cells and T helper 17 cells in pediatric non-Hodgkin lymphoma: a prospective study.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  327. OCHI Y, Hiramoto N, Ono Y, Yoshioka S, et al
    Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  328. NOY A, Lensing SY, Moore PC, Gupta N, et al
    Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.
    Leuk Lymphoma. 2015.
    PubMed     Text format    



  329. Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2015 nov 16. [epub ahead of print]. http://dx.doi.org/10.3109/10428194.2015.1094692.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  330. ARCARI A, Chiappella A, Spina M, Zanlari L, et al
    Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  331. ROSCH K, Scholz M, Hasenclever D
    Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  332. SARID N, Joffe E, Gibstein L, Avivi I, et al
    Reduced-dose ICE chemotherapy +/- rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    May 2015
  333. WIRTH A
    Putting radiotherapy into orbit.
    Leuk Lymphoma. 2015;56:1188-90.
    PubMed     Text format    


  334. SHIN SY, Lee ST, Kim HJ, Jang JH, et al
    A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12.
    Leuk Lymphoma. 2015;56:1550-1.
    PubMed     Text format    


  335. DAIFU T, Umeda K, Kouzuki K, Hamabata T, et al
    The NOD/Shi-scid/IL-2Rgamma(null) mice xenograft model recapitulates anaplastic large cell lymphoma dissemination to the bladder.
    Leuk Lymphoma. 2015;56:1542-3.
    PubMed     Text format    


  336. NIKOLAOU V, Papadavid E, Ekonomidi A, Dalamaga M, et al
    Association of clinicopathological characteristics with secondary neoplastic lymphoproliferative disorders in patients with lymphomatoid papulosis.
    Leuk Lymphoma. 2015;56:1303-7.
    PubMed     Text format     Abstract available


  337. BOHERS E, Mareschal S, Bertrand P, Viailly PJ, et al
    Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
    Leuk Lymphoma. 2015;56:1213-22.
    PubMed     Text format     Abstract available


  338. WASIK AM, Priebe V, Lord M, Jeppsson-Ahlberg A, et al
    Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
    Leuk Lymphoma. 2015;56:1425-31.
    PubMed     Text format     Abstract available


  339. BOI M, Zucca E, Inghirami G, Bertoni F, et al
    PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.
    Leuk Lymphoma. 2015;56:1223-8.
    PubMed     Text format     Abstract available


  340. RUEDA A, Olmos D, Vicioso L, Quero C, et al
    Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2015;56:1286-94.
    PubMed     Text format     Abstract available


  341. ALGRIN C, Faguer S, Lemiale V, Lengline E, et al
    Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma.
    Leuk Lymphoma. 2015;56:1240-5.
    PubMed     Text format     Abstract available


  342. BOULIOTIS G, Bessell EM
    Hodgkin disease (1973-2002): long-term survival and cure fractions.
    Leuk Lymphoma. 2015;56:1278-85.
    PubMed     Text format     Abstract available


  343. MCQUILLAN AD, Macdonald WB, Turner JH
    Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
    Leuk Lymphoma. 2015;56:1271-7.
    PubMed     Text format     Abstract available


  344. HILL BT, Tubbs RR, Smith MR
    Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.
    Leuk Lymphoma. 2015;56:1552-3.
    PubMed     Text format    


    April 2015
  345. SCHNEEWEISS M, Porpaczy E, Koch M, Jonak C, et al
    Transformed Mycosis Fungoides: Bridging to allogeneic stem cell transplantation with Brentuximab Vedotin.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    March 2015
  346. FILANOVSKY K, Yacobi R, Vorst E, Barshack I, et al
    Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
    Leuk Lymphoma. 2015;56:823-5.
    PubMed     Text format    


  347. BARTRAM T, Burkhardt B, Wossmann W, Seidemann K, et al
    Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Munster Study Group.
    Leuk Lymphoma. 2015;56:814-6.
    PubMed     Text format    


  348. YAN M, Callum J, Lin Y
    Hyperhemolysis associated with marginal zone lymphoma.
    Leuk Lymphoma. 2015;56:829-31.
    PubMed     Text format    


  349. HE J, Wang F, Zhu JH, Chen W, et al
    No association between MTR rs1805087 A > G polymorphism and non-Hodgkin lymphoma susceptibility: evidence from 11 486 subjects.
    Leuk Lymphoma. 2015;56:763-7.
    PubMed     Text format     Abstract available


  350. GEORGIADI EC, Dimtsas GS, Vassilakopoulos TP, Pangalis GA, et al
    Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma.
    Leuk Lymphoma. 2015;56:748-54.
    PubMed     Text format     Abstract available


  351. ODEJIDE OO, Cronin AM, Davidoff AJ, LaCasce AS, et al
    Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
    Leuk Lymphoma. 2015;56:716-24.
    PubMed     Text format     Abstract available


  352. ILLIDGE T, Bouabdallah R, Chen R, Gopal AK, et al
    Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Leuk Lymphoma. 2015;56:703-10.
    PubMed     Text format     Abstract available


  353. TOMITA N, Takasaki H, Ishiyama Y, Kishimoto K, et al
    Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Leuk Lymphoma. 2015;56:725-9.
    PubMed     Text format     Abstract available


  354. SAVORANI C, Manfe V, Biskup E, Gniadecki R, et al
    Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.
    Leuk Lymphoma. 2015;56:739-47.
    PubMed     Text format     Abstract available


  355. QUACKENBUSH RC, Horner TJ, Williams VC, Giampietro P, et al
    Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab.
    Leuk Lymphoma. 2015;56:779-81.
    PubMed     Text format    


  356. MAEGAWA S, Kuroda J, Kobayashi T, Fuchida S, et al
    Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:785-8.
    PubMed     Text format    


  357. TSAI JP, Iams WT, Greer JP, Morgan DS, et al
    Alternative intensive induction chemotherapeutic regimens in MYC expressing diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:797-800.
    PubMed     Text format    


  358. MANT S, Taylor G, Dutton D, Butler A, et al
    Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six cases.
    Leuk Lymphoma. 2015;56:774-8.
    PubMed     Text format    


  359. SCHMIDT C, Fingerle-Rowson G, Boehme A, Brendel K, et al
    Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
    Leuk Lymphoma. 2015;56:694-702.
    PubMed     Text format     Abstract available


  360. YOO C, Yoon DH, Yoon S, Kim S, et al
    Prognostic impact of beta(2)-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2015;56:688-93.
    PubMed     Text format     Abstract available


  361. ZHANG LN, Wang L, Fang C, Zou ZJ, et al
    The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:676-81.
    PubMed     Text format     Abstract available


  362. TSAI HT, Pfeiffer RM, Warren J, Wilson W, et al
    The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:682-7.
    PubMed     Text format     Abstract available


  363. PARASOLE R, Petruzziello F, Messina C, Barisone E, et al
    Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Leuk Lymphoma. 2015;56:650-5.
    PubMed     Text format     Abstract available


  364. FLAMMIGER A, Bacher U, Christopeit M, Horn C, et al
    Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance.
    Leuk Lymphoma. 2015;56:639-44.
    PubMed     Text format     Abstract available


    February 2015
  365. PHILLIPS AA, van Besien K
    A New "age" for High Dose Therapy and Autologous Stem Cell Transplantation.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    October 2014
  366. JAMROZIAK K, Tadmor T, Robak T, Polliack A, et al
    Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
    Leuk Lymphoma. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: